1. Home
  2. JAGX vs RENX Comparison

JAGX vs RENX Comparison

Compare JAGX & RENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$2.38

Market Cap

4.4M

Sector

Health Care

ML Signal

HOLD

Logo RenX Enterprises Corp. Common Stock

RENX

RenX Enterprises Corp. Common Stock

HOLD

Current Price

$1.06

Market Cap

4.2M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
JAGX
RENX
Founded
2013
2021
Country
United States
United States
Employees
N/A
38
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4M
4.2M
IPO Year
2014
2023

Fundamental Metrics

Financial Performance
Metric
JAGX
RENX
Price
$2.38
$1.06
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 2.0M
122.6K
Earning Date
11-16-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.42
N/A
EPS
N/A
★ N/A
Revenue
★ $11,511,000.00
$8,220,449.00
Revenue This Year
$77.78
$109.28
Revenue Next Year
N/A
$53.56
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 3860.67
52 Week Low
$0.20
$1.15
52 Week High
$41.53
$203.14

Technical Indicators

Market Signals
Indicator
JAGX
RENX
Relative Strength Index (RSI) 45.70 25.38
Support Level $2.12 N/A
Resistance Level $3.07 $2.12
Average True Range (ATR) 0.52 0.19
MACD -0.40 -0.07
Stochastic Oscillator 10.58 8.22

Price Performance

Historical Comparison
JAGX
RENX

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

About RENX RenX Enterprises Corp. Common Stock

RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.

Share on Social Networks: